Information Provided By: 
Fly News Breaks for August 2, 2019
MNTA
Aug 2, 2019 | 14:15 EDT
Stifel analyst Derek Archila reiterated his Buy rating on Momenta shares following the company's Q2 report and clinical updates, stating that he is encouraged by recent progress for the nipocalimab program. He believes its newest announced indication in warm autoimmune hemolytic anemia "offers a nice commercial opportunity with solid biological rationale," Archila tells investors. Though catalysts are still 12-15 months away, he sees the shares at "a compelling entry point" and maintains a $29 price target on the stock.
News For MNTA From the Last 2 Days
There are no results for your query MNTA
